

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

Andreas Kronbichler^{1,2}, Hans-Joachim Anders³, Gema Maria Fernandez-Juárez⁴, Jürgen Floege⁵, Dimitrios Goumenos⁶, Mårten Segelmark⁷, Vladimir Tesar⁸, Kultigin Turkmen⁹, Cees van Kooten¹⁰, Annette Bruchfeld^{11,12}, on behalf of the Immunonephrology Working Group of the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association)

1 Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria

2 Department of Medicine, University of Cambridge, Cambridge, UK

3 Division of Nephrology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Munich, Germany

4 Department of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain

5 Division of Nephrology, RTWH Aachen University Hospital, Aachen, Germany

6 Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece

7 Division of Nephrology, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden

8 Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

9 Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey

10 Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands

11 Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

12 Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

Correspondence to: Andreas Kronbichler; E-mail: andreas.kronbichler@i-med.ac.at

Twitter handles: @AKronbichler, @hjanders_hans, @AnnetteBruchfel, @ERAEDTA



ABSTRACT

Coronavirus Disease 19 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of SARS-CoV-2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs. Here, members of the Immunonephrology Working Group (IWG) of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) discuss thirteen frequently-asked questions regarding safety and efficacy of the most promising vaccine candidates. Post-marketing surveillance should be performed to estimate the rate of vaccine response (humoral and cellular) of different vaccine platforms, and surveillance of disease activity following administration of COVID-19 vaccines. Some of the candidates induce signaling pathways which also promote autoimmune kidney diseases, e.g. type I interferons in systemic lupus erythematosus. Efficacy estimates would thus far favor the use of selected COVID-19 vaccines, such as BNT162b2, mRNA-1273 or Gam-COVID-Vac. Humoral immune response after vaccination should be monitored using appropriate assays. Even in the absence of neutralizing antibodies patients might be protected by a sufficient cellular immune response capable to reduce severity of COVID-19. A reduced vaccine response after the use of CD20-depleting agents is anticipated, and it is particularly important to discuss strategies to improve vaccine response with these patients. Distancing and shielding measures remain important as not all vaccines fully protect from coronavirus infection. In-depth information about the most pressing vaccine questions is essential to reduce vaccine hesitancy of patients.

Keywords: COVID-19, glomerulonephritis, immunity, immune response, vaccine

ADDITIONAL CONTENT

An author video to accompany this article is available at: https://academic.oup.com/ndt/pages/author_videos.

INTRODUCTION

Coronavirus Disease 19 (COVID-19) remains a global threat. Risk factors predicting a severe disease course have been defined for kidney transplant recipients, patients with chronic kidney disease (CKD) and dialysis. There is a paucity of information about the risk for patients with immune-mediated kidney diseases [1]. A first analysis of the International Registry of COVID infection in glomerulonephritis (IRoc-GN) reported outcome of 40 patients with glomerulonephritis and COVID-19. In comparison to control cases, mortality was higher (15%) and acute kidney injury more frequently present (39%) in cases with glomerulonephritis [2]. Medications to reduce COVID-19 mortality remain largely elusive. Dexamethasone at a dose of 6 mg prevented COVID-19 related death in the RECOVERY trial [3]. Contrasting to this, investigations involving immune-mediated diseases provided evidence that a corticosteroid dose equally to or greater than 10 mg prior to infection is an independent risk factor for mortality [4]. These findings suggest that the underlying mechanisms leading to severe COVID-19 may differ in these patients, and in combination with high mortality rates provide a strong argument that patients with immune-mediated kidney diseases should be prioritized to receive a COVID-19 vaccine [5].

Different vaccine candidates have received emergency use authorization by agencies around the globe. The reported efficacies are variable, ranging from 50.4% for an inactivated vaccine candidate to 91.6%, 94.1% and 95% for Gam-COVID-Vac, mRNA-1273 and BN162b2 (Table 1-2) [6-8]. Exclusion criteria in these vaccine studies included autoimmune conditions requiring immunomodulatory therapy or the chronic use of immunosuppression, thus no information on efficacy in patients with immune-mediated kidney diseases is available to date. Here, board members of the Immunonephrology Working Group (IWG) of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) discuss thirteen frequently asked questions relevant to this context (Table 3).

1. Is vaccination recommended to patients with kidney disease?

We do recommend vaccination for everyone (except for those with known allergic reactions to any of the vaccine components).

Patients with immune-mediated disease have typically been excluded from all major trials and data on vaccine efficacy, particular safety (relapse/recurrence risk) and specific adverse events will only become available during the ongoing pharmacovigilance studies. CDC interim clinical guidance states: “Immunocompromised individuals may still receive COVID-19 vaccination if they have no contraindications to vaccination. However, they should be counseled about the unknown vaccine safety profile and effectiveness in immunocompromised populations, as well as the potential for reduced immune responses” [9]. The potential of COVID-19 vaccines to induce immunity protecting from severe COVID-19 should outweigh potential risks in most cases.

2. Is one vaccine better than others?

Full trial publications of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Gam-COVID-Vac (Sputnik V, Gamaleya) showed a high efficacy on preventing symptomatic and severe COVID-19, while the duration of protection and the potential of the available vaccines to prevent asymptomatic SARS-CoV-2 infection has not yet been fully explored. It is also not known, if any single vaccine offers advantage for specific patient populations.

Published trials with efficacy estimates included a “healthy” population, with co-morbidities present in 20.9% of participants in the BNT162b2 trial (0.7% with “renal disease”) [7], in a small proportion of participants in the mRNA-1273 trial (9.5% with diabetes, 5.0% with significant cardiac disease, and chronic lung disease in 4.7%) [6], a similar frequency in the ChAdOx1 nCoV-19 trial (respiratory disease 9.9%, cardiovascular disease 12.6%, and diabetes in 2.8%) [10-11] and Gam-COVID-Vac trial (concomitant diseases in 24.7%) [8]. Vaccine efficacy in patients with immune-mediated diseases needs to be defined. Estimates of vaccine protection of different platforms are summarized in Table 1. A specific discussion about differences in trial design and the difference between cellular and humoral immunity is necessary to reduce the existing uncertainty whether a specific vaccine is more effective than others. Importantly, all vaccine candidates showed high efficacy to prevent severe COVID-19 including hospitalizations (Table 2). The total number of severe/hospitalized cases was low, given the selection of the study population.

Efficacy endpoints in the BNT162b2 trial included development of COVID-19 seven days after the second dose (28 days after administration of the first dose) as primary endpoint and severe COVID-19 after the first dose as major secondary endpoint. COVID-19 occurred in 8 patients after the second dose in the BNT162b2 arm compared to 162 trial participants in the placebo arm. These results were consistent among older participants (≥ 65 years; or 75 years) and those considered at risk, defined by having a comorbidity. Severe COVID-19 occurred in one participant randomized to receive the vaccine as compared to 9 in the control arm [7].

The primary endpoint in the mRNA-1273 vaccine trial was defined as SARS-CoV-2 infection two weeks after the second dose (42 days after the first dose). The endpoint was reached by 196 cases, 11 in the mRNA-1273 arm and 185 cases in the placebo group. These findings were consistent across defined subgroups (age, sex, race and ethnic group). Severe COVID-19 occurred in 30 participants, of whom all were assigned to receive placebo. Seven COVID-19 cases were reported after the first mRNA-1273 dose compared to 46 cases in the placebo arm [6].

The primary objective of the ChAdOx1 nCoV-19 trial was to evaluate the efficacy of the vaccine against nucleic acid amplification test-confirmed COVID-19. Combined efficacy analysis fourteen days after the second dose included patients receiving a low-dose/standard-dose (LD/SD) and SD/SD vaccine strategy. Thirty cases (0.5%) among 5807 participants in the ChAdOx1 nCoV-19 group and 101 cases (1.7%) in the control group contracted symptomatic COVID-19, resulting in a vaccine efficacy of 70.4% [10]. Further investigations indicated that a higher vaccine efficacy can be obtained with a longer prime-boost interval, with a vaccine efficacy of 82.4% when the second dose was delayed by 12 weeks or more in comparison to 54.9% in those with a delay below 6 weeks. A similar frequency of asymptomatic infections was reported in both arms, indicating that there is suboptimal protection against transmission of SARS-CoV-2 [11]. No peer-reviewed information is however currently present in participants older than 55 years. Concerns have been raised that the ChAdOx1 nCoV-19 trials included too few elderly trial participants to inform about efficacy. Relevant data will be obtained from real-world experience and ongoing investigations in the UK and Israel, that started earlier than others their vaccination programs. Several authorities have advised against its use in people over 65 years [12]. This hesitancy to use ChAdOx1 nCoV-19 in most vulnerable age groups might also be extended to people with underlying medical conditions, such as patients with immune-mediated kidney diseases where a lower seroconversion rate to vaccination needs to be expected. Nonetheless, preliminary real-life data from Scotland indicated that ChAdOx1 nCoV-19 prevents COVID-19 related hospitalizations even in elderly populations.

Twenty-one days after the first dose of Gam-COVID-Vac (Sputnik V, rAd26 at day 0 and rAd5 at day 21), a 91.6% vaccine efficacy was shown. The observed vaccine efficacy was consistent among different age groups, with 91.8% efficacy reported in participants older than 60 years. Importantly, no moderate or severe cases of COVID-19 were reported in the vaccine arm, while 20 such events were recorded in the placebo group [8].

Based on the efficacy estimates provided by the published phase 3 trials, patients with immune-mediated kidney diseases should receive the most effective vaccines to improve chances of an adequate protection from COVID-19. Based on this criterion, we would recommend the use of BNT162b2, mRNA-1273 or potentially Gam-COVID-Vac.

3. I had COVID-19 recently. Should I be vaccinated?

Antibodies are decreasing over time, so theoretically there is a benefit, but data on the number of booster injections and an optimal time-point for vaccination after infection are scarce.

As vaccine rollout is slow in most countries and vulnerable patient groups are not being vaccinated in a satisfactory speed, it may be argued that it is unethical to prioritize patients with recent infection and the presence of antibodies. An argument to pursue vaccination is the possibility of reinfection. Single reinfection cases have been reported. These patients did not exhibit immunodeficiency and antibodies to SARS-CoV-2 after the first infection were either absent or not tested. Two of the four cases had a worse disease outcome at reinfection, further underlining that the first infection does not provide lifelong immunity [13]. However, with new mutations evolving the risk of reinfection is real [14]. Persistence of SARS-CoV-2 infections has been reported in patients receiving immunosuppressive drugs, and in particular with rituximab therapy [15, 16].

It has to be determined whether a single dose as a “booster” is sufficient to mount an adequate response and protect against reinfection. Recent data suggest that administration of a single vaccine dose of BNT162b2 or mRNA-1273 in individuals with pre-existing immunity leads to

an antibody response which is equal to or even exceed titers found in naïve individuals following their second dose [17].

4. Can I be vaccinated while taking immunosuppression?

States of immunodeficiency, hereditary or acquired, can reduce vaccine responses. A recent dose of rituximab or higher doses of other immunosuppressants may specifically impair vaccine responses. Likely, it is wise for many patients to wait with vaccination until steroid doses are tapered to below 20 mg prednisone equivalent a day and 6 months have elapsed since last rituximab dose.

There is a paucity of data regarding COVID-19 vaccine responses in patients with immune-mediated kidney diseases. A study of 56 patients with systemic lupus erythematosus (SLE) with low SLEDAI scores indicated that patients had fewer seroconversions or 4-fold titer rises for influenza A/H1N1 and A/H3N2 compared to healthy controls. Response defined as titers ≥ 40 to influenza A/H3N2 was especially diminished in patients receiving azathioprine [18]. Similarly, in patients with granulomatosis with polyangiitis (GPA) with a good disease control, high seroconversion rates were reported, while seroconversion to A/H1N1 and geometric mean titers were lower in comparison to controls. Patients were either off or had a low intensity of immunosuppression during the study period [19]. Based on these findings, the response to COVID-19 vaccines may be sufficient in patients with low grades of disease activity and no or minimal immunosuppression.

A particular concern during the COVID-19 pandemic is the use of rituximab in several immune-mediated kidney diseases. Analysis of the COVID-19 Global Rheumatology Alliance indicated that 42/192 (21.9%) of rituximab users died of COVID-19, corresponding to an over 4-fold higher odds ratio of death when methotrexate is used as a reference. No in-depth information about diagnoses, disease state (new diagnosis, flare or maintenance stage) or concomitantly used treatment is given [4]. It is important to acknowledge that most patients survive COVID-19 after rituximab treatment, while there is a need to determine risk factors which are indicative of a poor disease course following rituximab. Rituximab impairs humoral immunity and vaccine response is diminished within the first months of administration. Subdividing patient groups in early vaccination (4-8 weeks) and late vaccination (6-10 months) following rituximab in rheumatoid arthritis showed that the early vaccination group did not exhibit an IgM or IgG response following influenza vaccine administration, while a significant IgG response (2.82-fold) was observed in patients receiving the vaccine 6-10 months after rituximab [20]. Four-fold titer increase was achieved in only 2/12 patients receiving an influenza vaccination 7-9 months following rituximab [21]. Thus, a few months should have elapsed between rituximab administration and vaccination, with an ongoing B cell repopulation that indicates the potential of a humoral vaccine response [22]. Nonetheless, it is unclear thus far, if an impaired humoral vaccine response is tantamount to no protection against COVID-19 at all, or if patients may still be protected against severe disease forms by other mechanisms such as cellular immunity. Vaccination early after rituximab should be weighed against the individual risk of infection with all potential sequela.

In kidney transplant recipients, the seroresponse rate after influenza vaccination decreased in a dose-dependent manner in patients receiving mycophenolate mofetil (MMF), while seroprotection was comparable to non-MMF users [23]. This implies that response to vaccines may be appropriate, but the quality of immune response may be impaired and likely depends on the dose of MMF used. Belimumab, which is increasingly used in the management of SLE, was not associated with increased odds of death (1/27), although cautious interpretation is necessary given the number of studied patients [4]. Analysis of a SLE cohort indicated that the

addition of belimumab to other treatment modalities did not further impair vaccine response to a 13-valent pneumococcal conjugate vaccine [24].

Limited information is available on the vaccine response in patients currently taking high doses of corticosteroids. In patients with chronic obstructive pulmonary disease, a systemic corticosteroid dose over 10 mg / day did not impair the response to a 23-valent pneumococcal polysaccharide vaccine [25]. In children with nephrotic syndrome, the response to a hepatitis B vaccine was comparable among children without and with (0.4-0.5 mg/kg body weight on alternate days) corticosteroid prescription [26].

Taken together, vaccine antibody response can be expected to be blunted in patients that recently received rituximab, while the impact on cellular immunity needs to be determined. Anti-metabolites impaired the quality of vaccine response following influenza vaccination. The effects of high doses corticosteroids on immune response need to be determined but we do not recommend administering a COVID-19 vaccine in situations where high doses of steroids are needed.

5. Are there specific side effects of vaccines?

The approved vaccines are generally well tolerated. Some report “*flu-like symptoms*” for one or several days following the second dose. Local reactions are frequently reported as with other vaccines.

Based on the currently available data, COVID-19 vaccines in general population seem to be safe. Pharmacovigilance is essential to obtain information about side effects in a real-life setting. In Norway, 23 very frail elderly patients died following BNT162b2 administration [27], but this might have been coincidental. In this regard, a discussion on approved vaccines with a focus on the safety profile is essential to provide relevant information and reduce vaccine hesitancy. In the BNT162b2 phase 3 trial, systemic reactogenicity to the vaccine was more frequent in recipients in the younger age group (16 to 55 years of age). Fatigue and headache were reported in over 50% of trial participants following the second dose. Fever ranging between 38.9 to 40°C was reported in 0.2% and 0.8% after the first and second vaccine dose, respectively. Serious adverse events related to BNT162b2 were reported in 4 (0%) of trial participants, while the overall rate of severe and life-threatening adverse events did not differ between both groups [7]. An increase in severity of systemic events was also found following the second dose in trial participants receiving mRNA-1273, and both injection-site and systemic adverse events were more common among younger participants (16 to <65 years of age). Serious related adverse events were reported more frequently in the mRNA-1273 group in comparison to the placebo arm (6 and 4, respectively). A similar frequency of serious adverse events were reported for mRNA-1273 and placebo-treated participants (147 and 153), with no reported increase in autoimmunity [6]. Serious adverse events were reported in 79 (0.7%) of participants receiving ChAdOx1 nCoV-19 in comparison to 89 events (0.8%) in the control group receiving MenACWY (meningococcal group A, C, W, and Y conjugate vaccine). Potential immune-mediated conditions (such as Crohn’s disease, ankylosing spondylitis, and vasculitis rash) were reported in 13 participants in the ChAdOx1 nCoV-19 arm, while 16 such events were recorded in the comparator arm [10]. “Flu-like illness” was the most common side effect following Gam-COVID-Vac administration. Allergic reactions were balanced, and no increase in immune-mediated disease was reported [8].

6. Is there a possibility that the vaccine induces an activation of my disease?

Patients with autoimmune diseases were excluded in the early studies. There are insufficient data, but the vaccines seem to be safe and experience from previous vaccine studies does not indicate an increased risk for relapse/recurrence.

Most immune-mediated kidney diseases have a relapsing-remitting disease course. The benefits of vaccination outweigh the risk of relapse/recurrence induced by a specific COVID-19 vaccine, as there is a high probability to be protected against severe COVID-19 disease.

No increase in SLEDAI scores was found 30 days after influenza vaccination in SLE patients, independent of prescribed treatment modality [18]. Thirty-one patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in remission were randomized to receive either an influenza vaccine or no vaccine. During the follow-up period, there was no change in ANCA titer or inflammatory parameters, and only a single disease relapse episode was recorded in a patient with microscopic polyangiitis 6 months after influenza vaccination [28], an event unlikely to be associated with the vaccine. A post-marketing surveillance study found a 3.6-fold higher incidence of nephrotic syndrome in the year post-vaccination with the 4CMenB vaccine, with the report of 4 cases among 49,000 vaccinated patients [29].

In conclusion, the risk to develop *de novo* or relapsing/recurring disease following COVID-19 vaccine administration seems to be low. Several pathways known to be implicated in vaccine response, i.e. Toll-like receptor 7 (TLR7) or production of type I interferon [30], are also induced in autoimmunity (i.e. in SLE) [31] and thus might pre-dispose patients to disease relapse. Follow-up within registries focusing on immune-mediated kidney diseases (IRoc-GN, COV-GN or others) is necessary to estimate the individual risk of disease flare following COVID-19 vaccination.

7. Should I get vaccinated even if there are existing allergies?

In general, “yes”, the whole process is supervised. We advise against the use of currently available vaccines in patients with known PEG or polysorbate allergies.

Authorities have issued warnings that individuals with known history of severe allergic reactions to any of the components of the COVID-19 vaccines should not be vaccinated. In case of known other allergies, patients should be monitored for a period of 30 minutes post vaccination, all others should be observed for 15 minutes. Post-marketing experience revealed that among the first 1.9 million doses of BNT162b2 administration, 21 events consistent with anaphylaxis were reported. Anaphylaxis is a rare event, but a risk assessment prior to vaccination should be performed and if allergic to PEG, patients may be ineligible to use a mRNA vaccine. Both, BNT162b2 and mRNA-1273, use excipient PEG to stabilize the lipid nanoparticle containing the mRNA, while the ChAdOx1 nCov-19 and Ad26.COV2.S vaccines use excipient polysorbate 80 as a stabilizer. If a patient develops anaphylaxis after the first dose, it may be justified to withhold the second dose or perform PEG skin testing to evaluate if a second dose can be administered or not [32]. As there is an expanding COVID-19 vaccine platform, patients with known severe anaphylaxis may be vaccinated once other candidates become available.

8. Am I having a lifelong protection against COVID-19 after vaccination?

For now, there is no information about the longevity of immunity following vaccination. Booster injections may become necessary to maintain anti-SARS-CoV-2 immunity. Viral mutations are frequent, and newer/modified vaccines may be used to protect against these variants.

In patients with immune-mediated diseases, a significant decline in antibody levels can be expected between 3 and 6 months (as discussed above). Antibody levels may be measured during routine controls as we need to understand the impact on presence of neutralizing antibodies on risk of SARS-CoV-2 infections and severity.

A particular concern is the development of “escape mutations”, the change of the Spike-protein shape and a potential loss of specific neutralizing antibody binding sites induced by COVID-19 vaccines. Wide-spread sequencing has revealed new variants which have been detected worldwide and are characterized by a higher transmissibility. These new variants include B.1.1.7 (the “UK” strain) and B.1.351 or N501Y.V2 (the “South African” variant). A reported lower activity and efficacy of mRNA vaccine-induced neutralizing antibodies, and a lower efficacy in trials reported for other vaccines (NVX-CoV2373, ChAdOx1 nCoV-19, and Ad26.COV2.S) [33, 34]. It is likely that COVID-19 vaccines need to be adjusted to accommodate key sequence changes of these new variants [34]. Thus, regular vaccinations comparable with seasonal influenza vaccination combating new variants may be necessary.

9. I failed to mount an adequate immune response to my first COVID-19 vaccine. Is it possible to receive another vaccine platform?

Yes, with the approval of more vaccines, there could be other options (such as respiratory booster vaccines under investigation), which might induce immunity.

We expect that patients on immunosuppressive drugs develop reduced and sometimes insufficient vaccine responses in comparison to individuals without these treatments. Strategies to overcome such impaired response need to be determined and are speculative at this time. Different COVID-19 vaccines will allow administration of several candidates. Absence of seroconversion may not reliably indicate a lack of protection from severe COVID-19. Cellular immunity may still be present but is more difficult to assess. Cytotoxic CD8⁺ T cells are involved in viral clearance. The relevance of CD8⁺ T cells was underlined by the finding that subjects with milder COVID-19 disease exhibited a greater number of memory CD8⁺ T cells in the respiratory tract in comparison to severe cases. A potent CD8⁺ T cell response is induced by replication-defective viral-vectored vaccines, while it depends on the adjuvant used and formulation of mRNA-based vaccines and shows a weak response upon vaccination with a protein subunit [35]. T cell responses to a variable degree were shown for BNT162b2, mRNA-1273 and ChAdOx1 nCoV-19 [36-38]. In non-human primates, the intranasal administration of adenovirus-vectored vaccines resulted in reduced shedding, a reduction of viral load in the respiratory tract and a prevention of SARS-CoV-2 infection [39-41]. Thus, in patients with a non-detectable humoral immunity, T cell response may be measured when possible (i.e. by ELISPOT techniques [42]) as a cellular immune response may protect against infection or eventually reduce the probability of severe disease courses.

10. Can I expect interference of the COVID-19 vaccine with my medication?

No such interactions are expected.

Based on our current understanding of mode of action of approved vaccines, no interactions between the COVID-19 vaccines and immunosuppression used in patients with immune-mediated kidney diseases are expected.

11. After receiving my first vaccine shot, do I still need to shield and can I infect others?

Vaccinated patients should continue to follow current guidance to protect themselves from exposure to COVID-19. Providing the vaccine to patients and their caregivers will reduce risk for infection or clinical COVID-19 disease, but they must continue practices of wearing masks, social distancing, and maintaining good hand hygiene even after vaccination.

At present, there is no evidence that mounting an adequate vaccine response protects others and one might still transmit and contract COVID-19, even if the severity of infections might be reduced. It is important to continue shielding measures, and these should be adapted according to one's individual risk. Vaccination at first protects the vaccinated person from severe COVID-19. To what extent the currently available vaccines can help to reduce viral transmission and hence case numbers in the population as a basis for public containment measures, is currently unclear.

12. I received another vaccine a week ago. Should I get vaccinated against COVID-19 now?

There should be a delay of at least two weeks before you should receive your COVID-19 vaccine. We advise that non-urgent vaccinations may be postponed, with the exception of meningococcal/pneumococcal vaccination when eculizumab/ravulizumab are used.

We advise that annual or regular vaccinations are still performed. The year 2020 has seen a dramatic decrease in cases with influenza [43], presumably due to measures such as washing hands and wearing a mask. Influenza vaccination during the 2019/2020 winter season led to significantly fewer SARS-CoV-2 infections among hospital employees and the general population [44-46], indicating that "trained immunity" may play a role in one's individual susceptibility to contract COVID-19. Other vaccines which are not deemed urgent should be postponed and should not be administered within 2 weeks prior/after receipt of the COVID-19 vaccine. Urgent vaccinations include vaccinations against meningococcal/pneumococcal strains when eculizumab or ravulizumab is used in the management of immune-mediated kidney diseases.

13. Does the formation of antibodies reflect antiviral immunity?

This is unclear at the moment. The formation of antibodies is perceived as a surrogate biomarker for antiviral protection but whether the detected antibodies are of a neutralizing type or whether protective immunity is present even at low or absent antibody levels will remain uncertain. Therefore, antibody testing has of yet not generally been recommended.

Most individuals exhibit a strong antibody response following COVID-19 vaccine administration. Eight weeks after receiving a second dose of mRNA-1273 or BNT162b2, high levels of spike protein (S) and receptor binding domain (RBD) neutralizing antibodies were detected [47]. Notably, S1-specific and virus neutralization antibody titers were higher in participants receiving BNT162b2 in comparison to samples of participants following a SARS-CoV-2 infection. Antibody levels peaked around day 29 (a week after the booster dose) and decreased over time but remained above the level of sera from convalescent patients 63 days after the booster dose [48]. A small subset of patients receiving Gam-COVID-Vac had a measurement of RBD and neutralizing antibodies by day 42. Seroconversion rate was close to 100% and the results indicated that antibody response was comparable among different age groups [8]. The published trials did not provide antibody measurements of participants who contracted COVID-19 following vaccination. Thus, there is no information if antibody formation elicits protection against COVID-19, or if specific antibody levels are indicative of protection. Further research in this field is necessary, but we can expect that patients with ongoing immunosuppression will have lower antibody levels compared to healthy subjects.

CONCLUSION

Even with the approval of several COVID-19 vaccine candidates “the pandemic will not end overnight”. Shortage of vaccine supply limits the “rollout” to vulnerable patient groups (i.e. those with immune-mediated kidney diseases). A vast majority of our patients are keen to receive a COVID-19 vaccine, but for others an in-depth discussion about safety and efficacy is necessary to reduce vaccine hesitancy. This is particularly important as many unscientific sources raise irrational safety issues, which have not been reported in one of the recent phase 3 trials. Interpretation of data and comparison of different vaccine platforms is difficult, as different efficacy endpoints were used in landmark trials.

In this position paper, we addressed thirteen important questions and addressed specific issues which need to be considered in patients with immune-mediated kidney diseases. More pressing questions will be answered during the coming months of the pandemic, including the potential of transmission of SARS-CoV-2 once an individual is immunized by a vaccine. We advise that all individuals living in the same household are vaccinated in a timely manner, as this is likely beneficial if somebody is not mounting an adequate vaccine response.

FUNDING

The Immunonephrology Working Group receives financial and logistic support from ERA-EDTA. H.-J.A. was supported by the Deutsche Forschungsgemeinschaft (AN372/24-1).

CONFLICT OF INTEREST STATEMENT

A.K. reports personal fees from Novartis, TerumoBCT, Miltenyi Biotech, Vifor Pharma and Alexion. H.-J.A. reports personal fees from Janssen, GSK, Bayer, Boehringer Ingelheim, AstraZeneca, Novartis, Kezar and Previpharma. J.F. reports personal fees from Amgen, Bayer, Calliditas, NovoNordisk, Omeros, Traverre and Vifor-Fresenius. A.B. reports personal fees from AstraZeneca, ChemoCentryx, Merck/MSD, Vifor, and Abbvie.

REFERENCES

1. Turner-Stokes T, Jiang E, Johnson N, *et al.* Serological screening for COVID-19 in patients with glomerular disease. *Kidney Int Rep* 2021. Online ahead of print.
2. Waldman M, Soler MJ, García-Carro C, *et al.* Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. *Kidney Int* 2021;99(1):227-237
3. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* 2020;NEJMoa2021436. Online ahead of print.
4. Strangfeld A, Schäfer M, Gianfrancesco MA, *et al.* Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2021. Online ahead of print.
5. Windpessl M, Bruchfeld A, Anders HJ, *et al.* COVID-19 vaccines and kidney disease. *Nat Rev Nephrol* 2021. Online ahead of print.
6. Baden LR, El Sahly HM, Essink B, *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384(5):403-416
7. Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;383(27):2603-2615
8. Logunov DY, Dolzhikova IV, Shcheblyakov DV, *et al.* Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021;397(10275):671-681
9. <https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>.
10. Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397(10269):99-111
11. Voysey M, Clemens SAC, Madhi SA, *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; Online ahead of print.
12. Boytchev H. Why did a German newspaper insist the Oxford AstraZeneca vaccine was inefficacious for older people-without evidence? *BMJ* 2021;372:n414
13. Iwasaki A. What reinfections mean for COVID-19. *Lancet Infect Dis* 2021;21(1):3-5
14. Sabino EC, Buss LF, Carvalho MPS, *et al.* Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet* 2021. Online ahead of print.
15. Choi B, Choudhary MC, Regan J, *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl J Med* 2020;383(23):2291-2293
16. Tepas PR, Hafezi W, Lutz M, *et al.* Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. *Br J Haematol* 2020;190(2):185-188
17. Krammer F, Srivastava K, the PARIS team, *et al.* Robust spike antibody responses and increased reactivity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv preprint doi: <https://doi.org/10.1101/2021.01.29.21250653>.
18. Holvast A, Huckriede A, Wilschut J, *et al.* Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. *Ann Rheum Dis* 2006;65(7):913-918
19. Holvast A, Stegeman CA, Benne CA, *et al.* Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. *Ann Rheum Dis* 2009;68(6):873-878

20. Westra J, van Assen S, Wilting KR, *et al.* Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. *Clin Exp Immunol* 2014;178(1):40-47
21. Eisenberg RA, Jawad AF, Boyer J, *et al.* Rituximab-treated patients have a poor response to influenza vaccination. *J Clin Immunol* 2013;33(2):388-396
22. Baker D, Roberts CAK, Pryce G, *et al.* COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. *Clin Exp Immunol* 2020;202(2):149-161
23. Scharpé J, Evenepoel P, Maes B, *et al.* Influenza vaccination is efficacious and safe in renal transplant recipients. *Am J Transplant* 2008;8(2):332-337
24. Nagel J, Saxne T, Geborek P, *et al.* Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. *Lupus* 2017;26(10):1072-1081
25. de Roux A, Schmidt N, Rose M, *et al.* Immunogenicity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. *Respir Med* 2004;98(12):1187-1194
26. La Manna A, Polito C, Foglia AC, *et al.* Reduced response to hepatitis B virus vaccination in boys with steroid-sensitive nephrotic syndrome. *Pediatr Nephrol* 1992;6(3):251-253
27. Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. *BMJ* 2021;372:n149
28. Jeffs LS, Peh CA, Jose MD, *et al.* Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. *Nephrology (Carlton)* 2015;20(5):343-351
29. De Serres G, Billard MN, Gariépy MC, *et al.* Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal. *Vaccine* 2019;37(35):4996-5002
30. Pardi N, Hogan MJ, Porter FW, *et al.* mRNA vaccines - a new era in vaccinology. *Nat Rev Drug Discov* 2018;17(4):261-279
31. Anders HJ, Bruchfeld A, Fernandez Juarez GM, *et al.* Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. *Nephrol Dial Transplant* 2020;35(6):920-925
32. Banerji A, Wickner PG, Saff R, *et al.* mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. *J Allergy Clin Immunol Pract* 2020. Online ahead of print
33. Muik A, Wallisch AK, Sängler B, *et al.* Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* 2021. Online ahead of print.
34. Moore JP, Offit PA. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. *JAMA* 2021. Online ahead of print.
35. Jeyanathan M, Afkhami S, Smaill F, *et al.* Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol* 2020;20(10):615-632
36. Folegatti PM, Ewer KJ, Aley PK, *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* 2020;396(10249):467-478
37. Corbett KS, Flynn B, Foulds KE, *et al.* Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N Engl J Med* 2020;383(16):1544-1555
38. Sahin U, Muik A, Derhovanessian E, *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and T. *Nature* 2020;586(7830):594-599

39. Bricker TL, Darling TL, Hassan AO, *et al.* A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. *bioRxiv* 2020;2020.12.02.408823
40. Hassan AO, Kafai NM, Dmitriev IP, *et al.* A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* 2020;183(1):169-184.e113
41. van Doremalen N, Purushotham J, Schulz J, *et al.* Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. *bioRxiv* 2021;2021.01.09.426058.
42. Clarke CL, Prendecki M, Dhutia A, *et al.* Longevity of SARS-CoV-2 immune responses in haemodialysis patients and protection against reinfection. *medRxiv* 2021; doi: <https://doi.org/10.1101/2021.01.22.21249865>
43. Sullivan SG, Carlson S, Cheng AC, *et al.* Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. *Euro Surveill* 2020;25(47)
44. Debisarun PA, Struycken P, Dominguez-Andres J, *et al.* The effect of influenza vaccination on trained immunity: impact on COVID-19. *medRxiv* 2020; doi: <https://doi.org/10.1101/2020.10.14.20212498>
45. Ragni P, Marino M, Formisano D, *et al.* Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes. *Vaccines (Basel)* 2020;8(4)
46. Marín-Hernández D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. *J Med Virol* 2020. Online ahead of print.
47. Wang Z, Schmidt F, Weisblum Y, *et al.* mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* 2021. Online ahead of print.
48. Sahin U, Muik A, Vogler I, *et al.* BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. *medRxiv* 2020; doi: <https://doi.org/10.1101/2020.12.09.20245175>

Table 1. COVID-19 vaccines and their efficacy in phase 3 trials, including the storage temperature and the number of doses used

Vaccine (manufacturer)	Participants (vaccine/control group)	Efficacy	Infections (vaccine vs. control arm)	Duration (months)	Countries involved in trial	Number of doses	Storage
<i>Inactivated virus</i>							
CoronaVac (Sinovac)	-	50.7%*, * ¹	-	-	Brazil	2	2-8°C
BBIBP-CorV (Sinopharm)	-	79.34%*	-	-	UAE	2	2-8°C
<i>Purified protein</i>							
NVX-CoV2373 (Novavax)	-	89.3%*	6 vs. 56		UK	2	2-8°C
<i>Replication-defective viral vector vaccine</i>							
ChaAdOx1 nCoV-19 (Oxford-Astra Zeneca)	5,807 vs. 5,829	70.4% (LD/SD: 90.0%; SD/SD: 62.1%)	30 vs. 101* ²	3.4	UK, Brazil	1-2	2-8%
Gam-COVID-Vac/Sputnik V (Gamaleya)	16,501 vs. 5,476	91.6%	16 vs. 62* ³	1.6	Russia	2	2-8%
Ad26.COV2.S (Janssen/Johnson & Johnson)		72%, 66%, 57%* (USA, Latin America, South Africa)	116 vs. 348		USA, Central/South America, South Africa	1	2-8%
<i>mRNA vaccines</i>							
BNT162b2 (Pfizer/BioNTech)	18,860 vs. 18,846	95%	8 vs. 162* ⁴	2	USA, Brazil, Argentina, South Africa	2	-20%/-70%
mRNA-1273 (Moderna)	15,181 vs. 15,170	94.1%	11 vs. 185* ²	2.1	USA	2	-20%

*based on press releases

*¹83.7% if very mild cases were excluded

*² Fourteen days after second dose

*³ 21 days after receiving the first dose (day of the second dose)

*⁴ Seven days after second dose

Table 2. Relevant endpoints of COVID-19 vaccine trials

Vaccine (manufacturer)	Positive cases	Protection symptomatic/severe COVID-19	from COVID-19	Protection from hospitalization
		<i>Inactivated virus</i>		
CoronaVac (Sinovac)	50.7%	83.7%		100%
BBIBP-CorV (Sinopharm)	79%	-		-
		<i>Purified protein</i>		
NVX-CoV2373 (Novavax)	89.3%	-		100%
		<i>Replication-defective viral vector vaccine</i>		
ChaAdOx1 nCoV-19 (Oxford-AstraZeneca)	70.4%	64.1%		100%
Gam-COVID-Vac/Sputnik V (Gamaleya)	91.6%	-		100%
Ad26.COV2.S (Janssen/Johnson & Johnson)	66%	85%		100%
		<i>mRNA vaccines</i>		
BNT162b2 (Pfizer/BioNTech)	95%	90%		100%
mRNA-1273 (Moderna)	94.1%	100%		100%

Table 3. Thirteen frequently asked questions related to COVID-19 vaccines

	Specific question?	Answers
1	Is vaccination recommended to patients with kidney disease?	We do recommend vaccination for everyone (except for those with known allergic reactions to any of the vaccine components).
2	Is one vaccine better than others?	Full trial publications of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Gam-COVID-Vac (Sputnik V, Gamaleya) showed a high efficacy on preventing symptomatic and severe COVID-19, while the duration of protection and the potential of the available vaccines to prevent asymptomatic SARS-Cov-2 infection has not yet been fully explored. It is also not known, if any single vaccine offers advantage for specific patient populations.
3	I had COVID-19 recently. Should I be vaccinated?	Antibodies are decreasing over time, so theoretically there is a benefit, but data on the number of booster injections and an optimal time-point for vaccination after infection are scarce.
4	Can I be vaccinated while taking immunosuppression?	States of immunodeficiency, hereditary or acquired, can reduce vaccine responses. A recent dose of rituximab or higher doses of other immunosuppressants may specifically impair vaccine responses. Likely, it is wise for many patients to wait with vaccination until steroid doses are tapered to below 20 mg prednisone equivalent a day and 6 months have elapsed since last rituximab dose.
5	Are there specific side effects of vaccines?	The approved vaccines are generally well tolerated. Some report “flu-like symptoms” one or several days following the second dose. Local reactions are frequently reported as with other vaccines.
6	Is there a possibility that the vaccine induces an activation of my disease?	Patients with autoimmune diseases were excluded in the early studies. There are insufficient data, but the vaccines seem to be safe and experience from previous vaccine studies does not indicate an increased risk for relapse/recurrence.
7	Should I get vaccinated even if there are existing allergies?	In general, “yes”, the whole process is supervised. We advise against the use of currently available vaccines in patients with known PEG or polysorbate allergies.
8	Am I having a lifelong protection against COVID-19 after vaccination?	For now, there is no information about the longevity of immunity following vaccination. Booster injections may become necessary to maintain anti-SARS-CoV-2 immunity. Viral mutations are frequent, and newer/modified vaccines may be used to protect against these variants.
9	I failed to mount an adequate immune response to my first COVID-19 vaccine. Is it possible to receive another vaccine platform?	Yes, with the approval of more vaccines, there could be other options (such as respiratory booster vaccines under investigation), which might induce immunity.
10	Can I expect interference of the COVID-19 vaccine with my medication?	No, no such interactions are expected.
11	After receiving my first vaccine shot, do I still need to shield and can I infect others?	Vaccinated patients should continue to follow current guidance to protect themselves from exposure to COVID-19. While providing the vaccine to patients and their caregivers will reduce risk for infection or clinical COVID-19 disease, they must continue practices of wearing masks, social distancing, and maintaining good hand hygiene even after vaccination.
12	I received another vaccine a week ago. Should I get vaccinated against COVID-19 now?	There should be a delay of at least two weeks before you should receive your COVID-19 vaccine. We advise that non-urgent vaccinations may be postponed, with the exception of meningococcal/pneumococcal vaccination when eculizumab/ravulizumab are used.
13	Does the formation of antibodies reflect antiviral immunity?	This is unclear at the moment. The formation of antibodies is perceived as a surrogate biomarker for antiviral protection but whether the detected antibodies are of a neutralizing type or whether protective immunity is present even at low or absent antibody levels will remain uncertain. Therefore, antibody testing has of yet not generally been recommended.